Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
By Patrick Wingrove (Reuters) – Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump. Novo Holdings last month closed a $16.5 billion deal to buy U.S.-based Catalent. The firm then sold three of Catalent’s plants used to complete the … Read more…